STOCK TITAN

[Form 4] RenovoRx, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

RenovoRx director Una S. Ryan was granted a stock option on 10/01/2025 to purchase 47,640 shares of common stock at an exercise price of $1.34 per share. The option vests in 12 equal monthly installments beginning 11/01/2025 and expires on 10/01/2035. Following the grant, Ms. Ryan directly beneficially owns 47,640 options. The Form 4 was signed on 10/02/2025 and shows the filing was made by a single reporting person.

Il direttore di RenovoRx Una S. Ryan ha ricevuto una stock option il 10/01/2025 per acquistare 47.640 azioni ordinarie a un prezzo di esercizio di $1,34 per azione. L'opzione matura in 12 rate mensili uguali a partire dal 11/01/2025 e scade il 10/01/2035. A seguito della concessione, la signora Ryan detiene direttamente 47.640 opzioni. Il Form 4 è stato firmato il 10/02/2025 e mostra che la presentazione è stata effettuata da una sola persona riportante.

La directora de RenovoRx Una S. Ryan recibió una opción de acciones el 01/10/2025 para comprar 47,640 acciones comunes a un precio de ejercicio de $1,34 por acción. La opción se adquiere en 12 cuotas mensuales iguales a partir del 11/01/2025 y vence el 01/10/2035. Después de la concesión, la Sra. Ryan posee directamente 47,640 opciones. El Formulario 4 fue firmado el 02/10/2025 y muestra que la presentación fue realizada por una sola persona reportante.

RenovoRx의 이사인 Una S. Ryan은(는) 2025년 10월 1일에 보통주 47,640주를 매수할 수 있는 행사가 $1,34의 행사가로 주식 옵션을 받았다. 이 옵션은 12회에 걸쳐 매월 같은 금액으로 베스팅되며 시작은 2025년 11월 1일이고 만료일은 2035년 10월 1일이다. 수여 후 미세스 라이언은 직접적으로 47,640개의 옵션을 보유하게 된다. Form 4는 2025년 10월 2일에 서명되었고, 제보는 단일 신고자에 의해 이루어졌음을 나타낸다.

La directrice de RenovoRx, Una S. Ryan, a reçu une option d'achat d'actions le 10/01/2025 pour acquérir 47 640 actions ordinaires à un prix d'exercice de 1,34 $ par action. L'option est acquise en 12 versements mensuels égaux à partir du 11/01/2025 et expire le 10/01/2035. Suite à l'attribution, Mme Ryan détient directement 47 640 options. Le Formulaire 4 a été signé le 02/10/2025 et indique que le dépôt a été effectué par une seule personne déclarant.

RenovoRx-Direktorin Una S. Ryan erhielt am 10/01/2025 eine Aktienoption zum Kauf von 47.640 Stammaktien zu einem Ausübungspreis von 1,34 $ pro Aktie. Die Option vestet in 12 gleichen monatlichen Raten beginnend am 11/01/2025 und läuft am 10/01/2035 aus. Nach der Gewährung besitzt Frau Ryan direkt vorteilhaft 47.640 Optionen. Das Formular 4 wurde am 02/10/2025 unterzeichnet und zeigt, dass die Einreichung von einer einzigen meldenden Person vorgenommen wurde.

مديرة RenovoRx Una S. Ryan مُنحت خيار أسهم في 10/01/2025 لشراء 47,640 سهمًا من الأسهم العادية بسعر ممارسة قدره $1.34 للسهم. يتسلم الخيار حق الاستحقاق في 12 دفعات شهرية متساوية تبدأ من 11/01/2025 وتنتهي صلاحيته في 10/01/2035. عقب المنحة، تمتلك السيدة رايان مباشرةً 47,640 خيارًا. تم توقيع النموذج 4 في 2025/10/02 ويُظهر أن التقديم تم من قبل شخص واحد مُبلغ عنه.

RenovoRx 董事 Una S. Ryan2025/10/01 获得一项股票期权,购买 47,640 股普通股,行使价格为每股 $1.34。该期权在 12 期内按月分期归属,自 2025/11/01 起分12次,每月等额归属,并于 2035/10/01 到期。授予后,Ms. Ryan 直接受益地持有 47,640 份期权。Form 4 于 2025/10/02 签署,显示提交由单一申报人进行。

Positive
  • None.
Negative
  • None.

Il direttore di RenovoRx Una S. Ryan ha ricevuto una stock option il 10/01/2025 per acquistare 47.640 azioni ordinarie a un prezzo di esercizio di $1,34 per azione. L'opzione matura in 12 rate mensili uguali a partire dal 11/01/2025 e scade il 10/01/2035. A seguito della concessione, la signora Ryan detiene direttamente 47.640 opzioni. Il Form 4 è stato firmato il 10/02/2025 e mostra che la presentazione è stata effettuata da una sola persona riportante.

La directora de RenovoRx Una S. Ryan recibió una opción de acciones el 01/10/2025 para comprar 47,640 acciones comunes a un precio de ejercicio de $1,34 por acción. La opción se adquiere en 12 cuotas mensuales iguales a partir del 11/01/2025 y vence el 01/10/2035. Después de la concesión, la Sra. Ryan posee directamente 47,640 opciones. El Formulario 4 fue firmado el 02/10/2025 y muestra que la presentación fue realizada por una sola persona reportante.

RenovoRx의 이사인 Una S. Ryan은(는) 2025년 10월 1일에 보통주 47,640주를 매수할 수 있는 행사가 $1,34의 행사가로 주식 옵션을 받았다. 이 옵션은 12회에 걸쳐 매월 같은 금액으로 베스팅되며 시작은 2025년 11월 1일이고 만료일은 2035년 10월 1일이다. 수여 후 미세스 라이언은 직접적으로 47,640개의 옵션을 보유하게 된다. Form 4는 2025년 10월 2일에 서명되었고, 제보는 단일 신고자에 의해 이루어졌음을 나타낸다.

La directrice de RenovoRx, Una S. Ryan, a reçu une option d'achat d'actions le 10/01/2025 pour acquérir 47 640 actions ordinaires à un prix d'exercice de 1,34 $ par action. L'option est acquise en 12 versements mensuels égaux à partir du 11/01/2025 et expire le 10/01/2035. Suite à l'attribution, Mme Ryan détient directement 47 640 options. Le Formulaire 4 a été signé le 02/10/2025 et indique que le dépôt a été effectué par une seule personne déclarant.

RenovoRx-Direktorin Una S. Ryan erhielt am 10/01/2025 eine Aktienoption zum Kauf von 47.640 Stammaktien zu einem Ausübungspreis von 1,34 $ pro Aktie. Die Option vestet in 12 gleichen monatlichen Raten beginnend am 11/01/2025 und läuft am 10/01/2035 aus. Nach der Gewährung besitzt Frau Ryan direkt vorteilhaft 47.640 Optionen. Das Formular 4 wurde am 02/10/2025 unterzeichnet und zeigt, dass die Einreichung von einer einzigen meldenden Person vorgenommen wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
RYAN UNA S

(Last) (First) (Middle)
C/O RENOVORX, INC.
2570 W EL CAMINO REAL, SUITE 320

(Street)
MOUNTAIN VIEW CA 94040

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RenovoRx, Inc. [ RNXT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (right to buy) $1.34 10/01/2025 A 47,640 (1) 10/01/2035 Common Stock 47,640 $0 47,640 D
Explanation of Responses:
1. The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2025.
/s/ Una S. Ryan 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did RenovoRx (RNXT) director Una S. Ryan report on Form 4?

Ms. Ryan reported an option grant dated 10/01/2025 to buy 47,640 shares at $1.34 per share.

When do the options granted to Una S. Ryan begin vesting?

The options vest in 12 equal monthly installments beginning on 11/01/2025.

What is the expiration date of the option grant reported for RNXT?

The option expires on 10/01/2035.

How many shares does the reported Derivative Security cover?

The reported derivative security covers 47,640 underlying shares of common stock.

Was the Form 4 filed jointly or by one reporting person?

The Form 4 was filed by one reporting person (individual filing).
Renovorx Inc

NASDAQ:RNXT

RNXT Rankings

RNXT Latest News

RNXT Latest SEC Filings

RNXT Stock Data

49.11M
32.43M
4.44%
24%
0.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW